(Q36106239)

12 August 2017

1 reference

title

Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer (English)

1 reference

12 August 2017

1 reference

Kaisary AV

1

1 reference

12 August 2017

publication date

1 January 2005

1 reference

Prostate Cancer and Prostatic Diseases

12 August 2017

published in

1 reference

12 August 2017

volume

8

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

140-151

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.pcan.4500800

12 August 2017

exact match

0 references

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Differences in health-related quality of life of prostate cancer patients based on stage of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Prostate cancer patients' support and psychological care needs: Survey from a non-surgical oncology clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Osteoclast-targeted therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Complications of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Cancer fear and mood disturbance after radical prostatectomy: consequences of biochemical evidence of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846--a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Secondary hormonal therapies in the treatment of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Tolerability of Antiandrogens in the Treatment of Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

7 January 2021

Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

7 January 2021

ACTIVE SURVEILLANCE WITH SELECTIVE DELAYED INTERVENTION: USING NATURAL HISTORY TO GUIDE TREATMENT IN GOOD RISK PROSTATE CANCER

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

7 January 2021

Costs of prostate cancer, metastatic to the bone, in the Netherlands

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

7 January 2021

Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

7 January 2021

4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

7 January 2021

Neoadjuvant hormonal therapy: the Canadian experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

7 January 2021

Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

7 January 2021

The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

7 January 2021

Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

7 January 2021

The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

7 January 2021

Progressive osteoporosis during androgen deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

7 January 2021

Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

7 January 2021

Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500800

7 January 2021

Identifiers

DOI

10.1038/SJ.PCAN.4500800

1 reference

12 August 2017

1 reference